articleThe LancetMar 30, 2025Closed access

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial

Nordic Life Science Pipeline (Canada) · Bavarian Nordic (United States) · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

59
total citations
FWCI
87.72
Percentile
100%
References
29
Citations per year

Authors

13

Topics & keywords

Keywords
  • Immunogenicity
  • Placebo
  • Medicine
  • Virus
  • Virology
  • Virus-like particle
  • Chikungunya
  • Double blind
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.